Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 for prevention of recurrent respiratory tract infections in young children with wheezing lower respiratory illness
2024-511581-37-00Phase 4Completed
- Sponsor
- OM Pharma
- Start
- Nov 2022
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
Phase 4, randomised, double-blind trial of OM-85 in Airways Infection (3 arms), sponsored by OM Pharma. Primary endpoint: Primary efficacy endpoint. Started Nov 2022; status: completed.
02
Drugs
OM-85
03
Conditions
Airways Infection
Beyond the preview
Go deeper on 2024-511581-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511581-37-00.